ASX Announcement

Sunshine Heart Completes Training for US Feasibility Trial

Sydney, Australia - 3 May 2007: Sunshine Heart, Inc. (ASX: SHC) announced today the completion of training of clinicians and other healthcare professionals at the six US medical centres scheduled to participate in the US Feasibility Clinical Trial of the company's C-Pulse™ heart assist device.

The training program was held in conjunction with the recent International Society of Heart and Lung Transplantation meeting in San Francisco. This program was a key step in preparation for the US Clinical Trial that is scheduled to commence in the second half of 2007 at internationally recognised research hospitals and medical centres that specialise in heart failure and cardiovascular diseases.

Heart failure cardiologists and cardiothoracic surgeons were among the 30 people involved in the C-Pulse™ training program. Representatives attended from each of the sites that will participate in the trial:

- Ohio State University Medical Center (Columbus, Ohio)
- Northwestern University Feinberg School of Medicine (Chicago, Illinois)
- Pennsylvania State University's Milton Hershey School of Medicine (Hershey, Pennsylvania)
- University of Florida College of Medicine (Gainesville, Florida)
- University of Louisville-Jewish Hospital (Louisville, Kentucky)
- University of Alabama at Birmingham (Alabama).

As Dr Abraham, a national co-principal investigator of the Clinical Trial, told the trainees: "Despite available therapies, up to forty percent of patients are moderately or severely disabled by systolic heart failure. There is a need for additional therapies to improve the status of patients. This approach to heart failure management using the C-Pulse™ has the potential to improve poor cardiac output."

Dr McCarthy, the other national co-principal investigator, said: "I am looking forward to offering mechanical support without the risks inherent in VAD technology, to much earlier heart failure patients."

The lecturers including Sunshine Heart's Medical Director Dr William Peters, other members of the Sunshine Heart staff and other clinicians who have had direct experience of the C-Pulse™ during the Pilot clinical trials in Australia and New Zealand, covered a range of topics, including patient management and surgical implant of C-Pulse™, clinical study design, protocol and reimbursement procedures.

"The participation of these prestigious physicians and their institutions in the C-Pulse™ clinical trial signals the clinical need for C-Pulse™ and, by extension, the market potential for C-Pulse™ at the completion of clinical development," said Donald Rohrbaugh, the Chief Executive Officer of Sunshine Heart.

For further information, please visit www.sunshineheart.com or contact:

Media
Daniella Goldberg PhD
+612 9237 2803 / 0416 211 067
dgoldberg@bcg.com.au

Sunshine Heart
Victor Windeyer
Chief Operating Officer
+61 2 8424 7700
victor.windeyer@sunshineheart.com

Don Rohrbaugh
Chief Executive Officer
+1 714 665 1951
don.rohrbaugh@sunshineheart.com

Brian Bolton
Chief Financial Officer
+61 2 8424 7700
brian.bolton@sunshineheart.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Stock Exchange.

About Sunshine Heart
Sunshine Heart (ASX: SHC) (www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse™ an implantable, non-blood contacting, mechanical heart assist device for the treatment of people with heart failure. Sunshine Heart listed on the ASX in September 2004 and has a presence in Australia, New Zealand and the United States of America.

Heart failure is a progressively worsening condition characterized by shortness of breath after mild exercise, fatigue, dizziness and fluid retention. Heart failure is caused by the inability of the heart to pump sufficient blood to meet the body's oxygen requirement. An estimated 325,000 people in Australia have symptomatic heart failure, with 22,000 hospital admissions for heart failure each year. Heart failure is believed to contribute to over 1.4 million days of hospitalization annually at a cost of more than $1 billion. Over 5 million people in the USA have heart failure.

C-Pulse™ is an implantable, non-blood contacting mechanical heart assist device powered by an external driver unit. The implantable cuff is placed around the aorta just above the heart. The balloon is inflated and deflated to the rhythm of the heart to improve blood supply to both the body and the heart muscle, while reducing the workload on the heart. The wearable external driver is linked by an air tube to the cuff, and detects the heart's natural rhythm and controls inflation and deflation of the cuff in synchrony with the heart.

Implantation of C-Pulse™ involves wrapping the cuff around the aorta. No incisions into the aorta are needed, so that the device never comes into contact with the patient's bloodstream. The cuff is designed to inflate in a way that rolls the wall of the aorta inward in a gentle 'thumb printing' manner. The cuff is inflated and deflated rhythmically to improve blood supply to the heart and body as well as reduce the workload of the heart.